Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development

British Journal of Cancer

Volumn 98, Issue 5, 2008, Pages 900-906

  Kuester, K ^a,c   Kovar, A ^b   Lupfert C ^b   Brockhaus, B ^b   Kloft, C ^a,c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MERCK KGAA   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Linear and nonlinear clearance; Matuzumab; Monoclonal antibody; Population pharmacokinetic

Indexed keywords

GEMCITABINE; IMMUNOGLOBULIN; MATUZUMAB;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; COLON CANCER; COMPARTMENT MODEL; CONTINUOUS INFUSION; COVARIANCE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG ELIMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONLINEAR SYSTEM; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 40349116242     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604265     Document Type: Article

References (34)

1. Brambell FW, Hemmings WA, Morris IG (1964) A theoretical model of gamma-globulin catabolism. Nature 203: 1352-1354
2. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56: 361-369
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345
4. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F, Milano G (1993) Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1873-1878
5. DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, Khan M, Tacey R, Hill H, Celniker A (2003) Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 20: 1885-1900
6. Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, Gibbs S, Saif OH, Dalton JT, Chan KK, Schlom J, Martin Jr EW, Sun D (2007) Population pharmacokinetics of humanized monoclonal antibody HuCC49ΔCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol 47: 227-237
7. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15: 637-640
8. Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11: 689-708
9. Harding J, Burtness B (2005) Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 41: 107-127
10. Jonsson EN, Karlsson MO (1999) Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51-64
11. Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21: 735-750
12. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 4: 773-783
13. Kloft C, Graefe EU, Tanswell P, Scott AM, Hofheinz R, Amelsberg A, Karlsson MO (2004) Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs 22: 39-52
14. Koleba T, Ensom MH (2006) Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy 26: 813-827
15. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C (2006) A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 17: 1007-1013
16. Kovarik JM, Nashan B, Neuhaus P, Clavien PA, Gerbeau C, Hall ML, Korn A (2001) A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther 69: 201-209
17. Kuester K, Kloft C (2006) Pharmacokinetics of monoclonal antibodies. In Pharmacokinetics and Pharmacodynamics of Biotech Drugs Meibohm B (ed) pp 45-91. Wiley-VCH Verlag: Weinheim
18. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73: 348-365
19. Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J, Xu Y, Gu J (2005) Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 19: 1978-1985
20. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic - pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20: 511-528
21. Morell A, Terry WD, Waldmann TA (1970) Metabolic properties of IgG subclasses in man. J Clin Invest 49: 673-680
22. Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, Totoritis MC (1999) A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin Pharmacol Ther 66: 246-257
23. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M (1987) Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 252: 549-560
24. Ng CM, Bruno R, Combs D, Davies B (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45: 792-801
25. Pan W (2001) Akaike's information criterion in generalized estimating equations. Biometrics 57: 120-125
26. Ritter CA, Arteaga CL (2003) The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 30: 3-11
27. Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M (2003) Anticancer antibodies. Am J Clin Pathol 119: 472-485
28. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E (1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53: 2379-2385
29. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232
30. Stern M, Herrmann R (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54: 11-29
31. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22: 175-184
32. Watanabe T, Shintani A, Nakata M, Shing Y, Folkman J, Igarashi K, Sasada R (1994) Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. J Biol Chem 269: 9966-9973
33. Wells A (1999) EGF receptor. Int J Biochem Cell Biol 31: 637-643
34. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE (2007) Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 47: 383-396